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Abstract It remains controversial whether adjuvant therapy
should be delivered to pathological T3N0M0 rectal cancer
without neoadjuvant chemoradiotherapy. Thus identification
of patients at high risk is of particular importance. Herein, we
aimed to evaluate whether the absolute peripheral blood
monocyte count can stratify the pathological T3N0M0M0 rec-
tal cancer patients in survival. A total of 270 pathological
T3N0M0 rectal cancer patients with total mesorectal
excision-principle radical resection were included. The opti-
mal cut-off value of preoperative monocyte count was deter-
mined by receiver operating characteristic curve analysis.
Overall survival and disease-free survival between low- and
high-monocyte were estimated by Kaplan–Meier method and
Cox regression model. The optimal cut-off value for mono-
cyte count was 595 mm3. In univariate analysis, patients with
monocyte counts higher than 595/mm3 had significantly infe-
rior 5-year overall survival (79.2 vs 94.2 %, P=0.006) and
disease-free survival (67.8 vs 86.0 %, P<0.001). With adjust-
ment for the known covariates, monocyte count remained to
be associated with poor overall survival (HR=2.55, 95 % CI
1.27–5.10; P=0.008) and disease-free survival (HR=2.63,
95 % CI 1.48–4.69; P=0.001). Additionally, the significant
association of monocyte count with disease-free survival was
hardly influenced in the subgroup analysis, whereas this cor-
relation was restricted to the males and patients with normal
carcinoembryonic antigen (CEA) level (<5 μg/L), tumor
grade II, and with adjuvant therapy. High preoperative
monocyte count is independently predictive of worse
survival of pathological T3N0M0 rectal cancer patients
without neoadjuvant chemoradiotherapy. Postoperative
adjuvant therapy might be considered for patients with
high-monocyte count.
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Introduction
Rectal cancer accounts for approximately 28 % of all colorec-
tal malignancies [1, 2]. Albeit that neoadjuvant chemoradio-
therapy (CRT) followed by total mesorectal excision (TME)
surgery is now recommended for clinical stage II/III rectal
cancer, it remains controversial whether this is applicable to
patients with clinical stage T3N0. Due to the great CRT ex-
penses and increased toxicities and other causes, it is a com-
mon phenomenon in China that parts of patients with clinical
stage T3N0 rectal cancer fail to receive neoadjuvant CRT at
the initial time. Additionally, some patients with clinical stage
T1–2N0 may be upstaged with pathological T3N0M0 after
radical resection. Thus, it is the question whether postopera-
tive adjuvant treatment should be delivered to those patients
who avoid preoperative chemoradiotherapy and are staged
with pathological T3N0 after complete radical resection.
Considering the inaccuracy of imaging, only pathological di-
agnosed T3N0 after resection were entered into this study. As
postoperative adjuvant chemotherapy is recommended to rec-
tal cancer staged with T4N0M0 (stage II) according to ESMO
guideline, these sort of patients are excluded for analysis.
Since the current evidence of significant advantage of neoad-
juvant over adjuvant chemoradiotherapy in the whole stage II/
III group of patients [3], it is not ethical to conduct a random-
ized controlled trial to investigate whether adjuvant treatment
could be safely omitted in this special group of patients at the
present time. Therefore, in the absence of definite knowledge
of the benefit from adjuvant treatment for T3N0 disease in the
TME era, it is of particular importance to identify high-risk
patients to obtain survival gains from adjuvant treatment and
low-risk patients to free from adjuvant treatment toxicities and
expenses.
Evidence indicates that cancer-associated inflammation
plays a key role in the development and survival of a broad
range of cancers [4]. Peripheral blood monocyte is the key
immune cell in the inflammatory response, and has been in-
dependently associated with the prognosis of various malig-
nancies, such as diffuse large B cell lymphoma [5], hepatocel-
lular carcinoma [6], cervical cancer [7], metastatic melanoma
[8], and lung adenocarcinoma [9]. However, it is still un-
known if monocyte can predict the survival of patients with
rectal cancer. This study assessed the prognostic impact of




This retrospective study was approved by the Institutional
Review Board at Sun Yat-sen University Cancer Center, and
individual informed consent was waived given the anony-
mous analysis of routine data. A total of 270 rectal cancer
patients who underwent TME between June 2004 and
November 2011 were included. All patients were pathologi-
cally staged T3N0M0 after surgery. Moreover, all patients
received complete preoperative evaluation, including
endorectal ultrasound, computed tomography (CT), magnetic
resonance imaging (MRI), chest radiography, blood count,
and liver function test. Baseline monocytes count was
established from peripheral blood samples within 1 week be-
fore the initiation of any treatment modality. To exclude the
influence of various comorbidities or other disease states, all
included patients had no self-reported acute infections or rec-
tal disorders, indicating that the cell counts could represent the
baseline value.
Treatment
Surgical resection was defined as radical when there was no
evidence of distant metastases and tumor clearance was both
macroscopically and histologically complete. All the opera-
tions were carried out according to the TME-principles by
colorectal surgeons, and the methods included low anterior
resection (LAR) and abdominoperineal resection (AR).
Follow-up
Patients were examined every 3 months during the first
2 years, with follow-up examinations every 6 months thereaf-
ter. Evaluations included complete blood count, liver function
test, CEA, CA19-9, physical examination, and digital rectal
examination. Chest radiography, CT scanning of the abdomen
and pelvis, and colonoscopy were conducted every 6 months
after surgery.
Statistical analysis
The optimal cut-off value of monocyte count was determined
using receiver operating characteristic (ROC) curve analysis.
At each value, sensitivity and specificity were plotted, thus
generating an ROC curve. The score closest to the point with
both maximum sensitivity and specificity was selected as the
cut-off value. Covariates balance between low- and high-
monocyte groups were examined by t test (continuous vari-
able), χ2 test, or Fisher’s exact test (categorical variable) as
appropriate.
The main endpoints were overall survival (OS) and
disease-free survival (DFS), defined as the time of surgery to
the date of death from all causes, and to the date of either
locoregional recurrence, distant metastasis, respectively. OS
and DFS rates were estimated with Kaplan–Meier method
and log-rank test. Multivariate analysis was performed by
Cox proportional hazards regression with backward LR
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method. Two-sided P<0.05 was considered to be statistically




The median follow-up of all patients was 53 months (range,
3–106 months). There were 19 (7.0 %) cases of locoregional
relapse, 37 (13.7 %) cases of distant metastasis, and 32
(11.9 %) cases of death, respectively. The 3- and 5-year OS
was 94.1 and 89.8 %, respectively, and the 3- and 5-year DFS
was 90.1 and 84.5 %, respectively.
According to the ROC curve analysis (Fig. 1), patients
were stratified into low- and high-monocyte group by the
optimal cut-off value of 595/mm3. The clinicopathological
characteristics were summarized in Table 1. Obviously,
high-monocyte count (≥595/mm3) was significantly associat-
ed with male (P<0.001), elevated CEA level (≥5 μg/L)
(P=0.016), and high tumor grade (P=0.031). However, pa-
tients with low-monocyte count (<595/mm3) were quite sim-
ilar to those with high-monocyte count in age, tumor location,
operation, and adjuvant chemotherapy.
OS and DFS according to monocyte count
The 3- and 5-year OS rate was 96.1 and 94.2 % for patients
with low-monocyte count, and 87.7 and 79.2 % for those with
high-monocyte count. Correspondingly, the 3- and 5-year
DFS rate was 91.6 and 86 % for patients with low-monocyte
count, and 75.8 and 67.8 % for those with high-monocyte
count, respectively. Apparently, patients with low-monocyte
count had significantly superior OS and DFS over those with
high-monocyte count (P=0.006 and P<0.001, respectively,
Fig. 2a, b).
Adjusting for the known covariates including sex, age,
CEA level, tumor location, operation, tumor grade, and adju-
vant chemotherapy, patients with high-monocyte count still
showed significantly higher risk of death (HR=2.55, 95 %
CI 1.27–5.10; P=0.008) and disease (HR=2.63, 95 % CI
1.48–4.69; P=0.001) than those with low-monocyte count
(Table 2).
Subgroup analysis
Given the above positive association of monocyte count with
sex, CEA level, and tumor grade, there might be possible
interactions between them. To clarify the influence, thus, we
did the subgroup analysis (Table 3). In the male patients,
monocyte count was independently associated with both OSFig. 1 Receiver operating characteristic analysis
Table 1 Comparison of clinicopathological characteristics between all
the pT3N0M0 patients with low- and high-monocyte counts
Characteristics <595/mm3 ≥595/mm3 P
No. % No. %
Sex <0.001
Male 102 55.1 66 77.6
Female 83 44.9 19 22.4
Age (years) 0.808
<61 90 48.6 40 47.1
≥61 95 51.4 45 52.9
CEA level 0.016
Normal 118 63.8 41 48.2
Elevated 67 36.2 44 51.8
Tumor location 0.772
≤5 cm 51 27.6 22 25.9
>5 cm 134 72.4 63 74.1
Operation 0.158
AR 151 81.6 63 74.1
APR 34 18.4 22 25.9
Tumor grade 0.031
I 9 4.9 10 11.8
II 164 88.6 65 76.5
III 12 6.5 10 11.8
Adjuvant therapy 0.361
No 58 31.4 22 25.9
Yes 127 68.6 63 74.1
AR anterior resection, APR abdominoperineal resection
Tumor Biol. (2015) 36:8213–8219 8215
(HR=2.85, 95 % CI 1.24–6.51; P=0.013) and DFS
(HR=2.73, 95 % CI 1.39–5.37; P=0.004). However, the
prognostic impact of monocyte count was observed for DFS
(HR=4.69, 95 % CI 1.44–15.34; P=0.011), but not for OS
(HR=1.55, 95% CI 0.29–8.24; P=0.606) among the females.
Similarly, the associations of monocyte count with DFS were
observed in all the patients regardless of the CEA level; nev-
ertheless, the significant relations of monocyte count with OS
were only obtained in the strata of patients with normal CEA
level. Additionally, monocyte count was significantly corre-
lated with OS and DFS among patients with tumor grade II,
instead of grades I and III. And for patients with adjuvant
therapy, monocyte count was the prognostic factor for OS
and DFS, whereas for those with operation alone, monocyte
count was just independently predictive of DFS.
Discussion
To our knowledge, this is the first large-scale study to evaluate
the prognostic significance of the absolute monocyte count in
pathological T3N0M0 rectal cancer patients treated with TME
resection and without undergoing preoperative chemoradio-
therapy. We demonstrated that high-monocyte count indepen-
dently predicted worse survival of patients. This finding was
highly consistent with those in hepatocellular carcinoma [6],
Fig. 2 Overall survival (a) and
disease-free survival (b) of
patients with low- and high-
monocyte counts
8216 Tumor Biol. (2015) 36:8213–8219
cervical cancer [7], metastatic melanoma [8], and lung adeno-
carcinoma [9].
Unfortunately, the biological reasons behind this correla-
tion remain speculative but previously published experimental
studies support the observation. Firstly, it may relate to the
insidious progression of cancer disease involving activation
of innate immunity [10]. Monocytes play a key role in innate
immunity, constitute nearly 5 % of the circulating white blood
cell pool, and exhibit a short half-life in the circulation of a
few hours [11]. The presence of immunocompetent cells with-
in tumors is assumed to reflect the immunological antitumor
response. Secondly, the causal link between inflammation and
cancer is now well established [12, 13]. Monocytes, known as
the key component of inflammation system, might directly
stimulate cancer cell growth by producing various proinflam-
matory cytokines, such as interleukin-1, interleukin-6, and
tumor necrosis factor. In addition, monocytes can be actively
attracted to the tumor site and differentiate into tumor-
associated macrophages (TAMs) via the cytokines and
chemokines produced by tumor cells, such as monocyte
chemoattractant protein-1 and vascular endothelial growth
factor [14, 15]. Thus, the circulating level of monocytes may
reflect formation or presence of TAMs. Many macrophage-
released soluble factors directly stimulate the growth of tumor
cells and promote tumor cell migration and metastasis [12, 16,
17]. Macrophages can produce enzymes and inhibitors that
Table 3 Subgroup analysis of the association between monocyte count and overall survival and disease-free survival
Subgroup Overall survival Disease-free survival
No. at risk/No. of events HR 95 % CI P* No. at risk/No. of events HR 95 % CI P*
Low- MO High-MO Low-MO High-MO
Sex
Male 102/9 66/15 2.85 1.24–6.51 0.013 102/15 66/21 2.73 1.39–5.37 0.004
Female 83/6 19/2 1.55 0.29–8.24 0.606 83/7 19/5 4.69 1.44–15.34 0.011
CEA level
Normal 118/8 41/9 3.38 1.31–8.78 0.012 118/10 41/10 3.96 1.60–9.78 0.003
Elevated 67/7 44/8 1.49 0.54–4.13 0.441 67/12 44/16 2.26 1.07–4.80 0.033
Tumor grade
I 9/2 10/1 – 0.960 9/3 10/1 1.40 0.05–40.79 0.844
II 164/12 65/14 3.05 1.41–6.59 0.005 164/18 65/22 2.91 1.54–5.50 0.001
III 12/1 10/2 – 0.874 12/1 10/3 4.63 0.24–88.40 0.309
Adjuvant therapy
No 58/6 22/4 1.35 0.35–5.14 0.662 58/7 22/7 3.20 1.05–9.75 0.041
Yes 127/9 63/13 3.26 1.39–7.64 0.007 127/15 63/19 2.97 1.51–5.86 0.002
HR hazard ratio, CI confidence interval, MO monocyte count
*Adjusted for sex, age (<61 vs ≥61 years), CEA level (<5 vs ≥5μg/L), tumor location (≤5 vs >5 cm), operation, tumor grade, and adjuvant chemotherapy
except the factor defined as the stratum
Table 2 Univariate and multivariate analysis of potential prognostic factors
Overall survival Disease-free survival
Unadjusted P Adjusted HR (95 % CI) Adjusted P Unadjusted P Adjusted HR (95 % CI) Adjusted P
Monocyte (<595/mm3 vs ≥595/mm3) 0.006 2.55 (1.27–5.10) 0.008 <0.001 2.63 (1.48–4.69) 0.001
Sex (male vs female) 0.115 0.63 (0.28–1.41) 0.258 0.046 0.59 (0.30–1.14) 0.117
Age (<61 vs ≥61 years) 0.530 1.23 (0.60–2.52) 0.581 0.069 1.65 (0.91–3.00) 0.096
CEA level (normal vs elevated) 0.704 1.01 (0.49–2.09) 0.977 0.011 1.72 (0.96–3.08) 0.070
Tumor location (≤5 vs >5 cm) 0.999 0.81 (0.30–2.14) 0.664 0.291 0.67 (0.37–1.24) 0.202
Operation (AR vs APR) 0.959 0.89 (0.38–2.08) 0.796 0.885 0.52 (0.22–1.21) 0.128
Tumor grade (I/II/III) 0.936 0.84 (0.39–1.81) 0.662 0.977 0.98 (0.50–1.93) 0.945
Adjuvant therapy (no vs yes) 0.574 0.76 (0.36–1.62) 0.482 0.885 0.88 (0.46–1.71) 0.713
AR anterior resection, APR abdominoperineal resection, HR hazard ratio, CI confidence interval
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regulate the digestion of the extracellular matrix, hence favor-
ing tumor invasion and migration [18, 19] and can also con-
tribute to tumor progression by secretion of factors that en-
hance neoangiogenesis [20]. Furthermore, TAMs can educate
and control invading leukocytes to promote angiogenesis, vi-
ability, motility, and invasion [21]. Additionally, the immuno-
suppressive activity of TAMs is performed indirectly by the
secretion of chemokines that attract T cell subsets lacking
cytotoxic function [12, 22]. It has been reported that the den-
sity of TAMs in many tumors correlates with increased angio-
genesis, tumor invasion, and poor prognosis [23–25]. And
numerous clinical studies support the protumorigenic role of
TAMs in human cancers, showing significant correlation be-
tween elevatedmacrophage content and poor clinical outcome
[23, 25, 26].
In the present study, high-monocyte count was positively
associated with male, CEA level, and high tumor grade
(Table 1), which suggested the potential interactions between
them. As shown in the subgroup analysis, all of these covar-
iates together with adjuvant therapy significantly affected the
association of monocyte count with OS, but not DFS. One of
the most important causes may be the small sample size of
included patients and a few deaths. Actually, only CEA level
was found to be strongly interacted with monocyte count for
OS (P=0.002). Since high CEA level is known to be an ad-
verse prognosis in rectal cancer, thus the prognostic impact of
monocyte count among patients with high CEA level, if
existed, was likely to be covered by the effect of CEA level.
It is one of the limitations that this was a retrospective study
with small sample size, which possibly caused skewed results;
however, the included patients were restricted to those diag-
nosed with pathological T3N0M0, which lowered the uncer-
tainty of staging by images. Moreover, the treatment hetero-
geneity, especially the influence of adjuvant chemotherapy,
was another limitation. But this was included in the multivar-
iate analysis and subgroup analysis, and resulted in small shift
to the overall outcomes.
In conclusion, the absolute number of preoperative periph-
eral blood monocyte count is an independent predictive factor
that can stratify the survival of rectal cancer patients staged
with pathological T3N0M0 after TME resection.
Postoperative adjuvant treatment might be considered for this
sort of patients with high-monocyte count.
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